KOTAI Biotechnologies
Osaka, JapanWebsite
A startup developing immune AI platforms for the analysis of antibody repertoires to accelerate the development of highly effective immunotherapies.
Loading company information...
A startup developing immune AI platforms for the analysis of antibody repertoires to accelerate the development of highly effective immunotherapies.
Company context
KOTAI Biotechnologies prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
KOTAI Biotechnologies is a pioneering Japanese biotechnology firm that specializes in the intersection of artificial intelligence and immunology. Founded in 2016 as a spin-out from the Immunology Frontier Research Center (IFReC) at Osaka University, the company focuses on immune repertoire analysis to accelerate drug discovery and biomarker identification. By leveraging proprietary AI platforms and deep structural knowledge of immune systems, KOTAI provides critical insights into complex biological data, supporting advancements in cancer, autoimmune, and infectious disease research.
KOTAI’s mission is to provide novel, groundbreaking biomarkers and drug discovery targets that have a significant impact on the medical and pharmaceutical industries, ultimately striving to improve healthcare for patients with unmet medical needs.
Founded
2016
Headquarters
Minoh, Osaka, Japan
Employees
11-50
Industry
Biotechnology
Opportunity to work at the cutting edge of AI and immunology research
Strong academic roots and collaboration with top-tier research institutions
Limited public information regarding internal employee benefits and compensation
Funding
Acquired by Sanyo Trading Co., Ltd.
Small team environment may lead to high individual workload